AGL 2043
AGL 2043 is an effective inhibitor of PDGFR (IC50=0.8 μM) and TEL-PDGFR kinases, as well as FLT3 and KIT kinases. AGL 2043 can effectively inhibit porcine cardiac smooth muscle cell proliferation and balloon-induced vascular stenosis, and is suitable for development as an anti-restenotic and anticancer agent.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 226717-28-8
- Formel: C15H12N4S
- Molecular Weight:280.35
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
IC50: 0.8 μM (PDGFR)[1].
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BaF3 | IC50 |
1 μM
Compound: 27; AGL 2043
|
Inhibition of human FLT3 expressed in mouse BAF3 cells assessed as reduction in tyrphostin activity incubated for 2 hrs followed by FLT3 ligand stimulation by immunoblot analysis
Inhibition of human FLT3 expressed in mouse BAF3 cells assessed as reduction in tyrphostin activity incubated for 2 hrs followed by FLT3 ligand stimulation by immunoblot analysis
|
[PMID: 30502116] |
| NIH3T3 | IC50 |
>30 μM
Compound: 27; AGL 2043
|
Inhibition of SRC in transformed mouse NIH3T3 cells by SDS-PAGE based immunoblot assay
Inhibition of SRC in transformed mouse NIH3T3 cells by SDS-PAGE based immunoblot assay
|
[PMID: 30502116] |
Chemical Information
-
CAS. Nr. 226717-28-8
-
Molecular Weight 280.35
-
Formel C15H12N4S
-
SMILES
CC(N1C)=NC2=C1C=C3N=CC(C4=CC=CS4)=NC3=C2
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)